A mixed performance in the stock price over the year has left investors unsure of what to expect, resulting in a range of outlooks from optimistic to pessimistic. The metric has seen a significant loss of -29.40% since the start of this calendar year. Looking back over the last six months, we can see a weaker performance of 80.92%. Over the past 30 days, the price of SYRS has leaped by -18.76%. And in the last five days, it has surged by 18.66%.
The market performance of Syros Pharmaceuticals Inc. has been somewhat stable. Over the past year, the company’s stock achieved a high of $8.17 on 01/02/24, with the lowest value for the same timeframe being $2.09, recorded on 10/19/23.
52-week price history of SYRS Stock
The history of a stock’s 52-week high and low prices can provide important information about its current state and future potential. Syros Pharmaceuticals Inc.’s current trading price is -32.68% away from its 52-week high, while its distance from the 52-week low is 163.13%. The stock’s price range for this period has been between $2.09 and $8.17. The Healthcare sector company’s shares saw a trading volume of about 0.99 million for the day, which was higher than the average daily volume of 0.2 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Syros Pharmaceuticals Inc. (SYRS) has experienced a quarterly decline of -20.29% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 145.47M and boasts a workforce of 68 employees.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 5.91, with a change in price of +2.81. Similarly, Syros Pharmaceuticals Inc. recorded 269,218 in trading volume during the last 100 days, posting a change of +104.46%.
SYRS’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for SYRS stands at 3.73. Similarly, the long-term debt-to-equity ratio is also 3.19.
SYRS Stock Stochastic Average
As of today, the raw stochastic average of Syros Pharmaceuticals Inc. over the last 50 days is at 29.00%. This shows a declinee from the raw stochastic average of the previous 20 days, which was recorded at 45.79%. Further, the company’s Stochastic %K and %D values for the last 20 days were 16.80% and 10.57%, respectively.
